PSU vaccine maker IIL to invest Rs 700 crore on new facility in Hyderabad

Indian Immunologicals Limited (IIL), a public sector vaccine maker owned by National Dairy Development Board (NDDB), on Monday said it will be investing Rs 700 crore to set up a greenfield animal vaccine manufacturing facility in Genome Valley, Hyderabad.

The proposed facility will be making Foot and Mouth disease (FMD) and other emerging diseases. The facility will create total employment for around 750 people.

The facility is intended to be a state-of-art fully integrated biosafety level 3 (BSL-3) for drug substance (DS) production and respective fill-finish.


The proposed facility will add another 300 million doses/annum of FMD vaccine to its existing capacity. The current facility in Gachibowli, Hyderabad has a capacity of 300 million doses. Production is scheduled to commence in the 3rd year.

IIL manufactures over 150 products, and is already one of the largest manufacturers of FMD vaccine in the world and is the leading supplier of FMD vaccine to the Government of India’s National Animal Disease Control Programme (NADCP).

“IIL is on an aggressive growth path and this third vaccine facility in Hyderabad will ensure self-sufficiency for our nation in the field of vaccines and thereby saving the exchequer and farmers several thousands of crores,” said K. Anand Kumar, MD of IIL.